|
Product Details:
|
| Purity: | 99.0%min | Type: | Pharmaceutical Intermediates |
|---|---|---|---|
| Cas No.: | 23964-57-0 | Product Name: | Articaine Hydrochloride |
| Color: | Light Yellow Powder | Storage: | Cool And Dry Place |
| Shelf Life: | 2 Years | Moq: | 10g |
| Delivery Time: | In 3 Days Send Out | Payment Term: | T/t Bank Transfer / Btc |
| Payment Way: | WU | ||
| High Light: | Articaine HCl Powder CAS 23964-57-0,99.0% Articaine Hydrochloride |
||
Product Description
| Articaine hydrochloride Basic information |
| Uses |
| Product Name: | Articaine hydrochloride |
| CAS: | 23964-57-0 |
| MW: | 320.839 |
| Product Categories: | API;research chemical;local anesthetic;Pharmaceutical intermediate;BDO |
| Mol File: | 23964-57-0.mol |
| Articaine hydrochloride Chemical Properties |
| Melting point | 177-178° |
| storage temp. | Keep in dark place,Inert atmosphere,2-8°C |
| solubility | H2O: soluble20mg/mL, clear |
| form | powder |
| color | white to beige |
| Stability: | Hygroscopic |
Avanafil Applications:
Avanafil is a PDE5 inhibitor approved for erectile dysfunction by FDA on April 27, 2012 and by EMA on June 21, 2013. Avanafil acts by inhibiting a specific phosphodiesterase type 5 enzyme which is found in various body tissues, but primarily in the corpus cavernosum , as well as the retina.The advantage of avanafil is that it has very fast onset of action compared with other PDE5 inhibitors. It is absorbed quickly, reaching a maximum concentration in about 30–45 minutes. About two-thirds of the participants were able to engage in activity within 15 minutes.
| Melting point | 298-300°C |
| alpha | D20 +71.0° |
| Boiling point | 679.1±55.0 °C(Predicted) |
| density | 1.51±0.1 g/cm3(Predicted) |
| Fp | 2℃ |
| storage temp. | Sealed in dry,2-8°C |
| solubility | DMSO: soluble20mg/mL, clear |
| pka | 16.68±0.40(Predicted) |
| form | powder |
| color | white to beige |
| optical activity | [α]/D +68 to +78°, c = 1 in chloroform-d |
| InChIKey | WOXKDUGGOYFFRN-IIBYNOLFSA-N |
Description
Articaine is an intermediate-potency, short-acting amide local anesthetic with a fast metabolism due to an ester group in its structure. It is effective with local infiltration or peripheral nerve block in dentistry, when administered as a spinal, epidural, ocular, or regional nerve block, or when injected intravenously for regional anesthesia.
In comparative trials, its clinical effects were not generally significantly different from those of other short-acting local anesthetics and chloroprocaine, and there is no conclusive evidence demonstrating above-average neurotoxicity. Articaine proved to be suitable and safe for procedures requiring a short duration of action in which a fast onset of anesthesia is desired, eg, dental procedures and ambulatory spinal anesthesia, in normal and in special populations.
Structure and metabolism
The amide structure of articaine is similar to that of other local anesthetics, but its molecular structure differs through the presence of a thiophene ring instead of a benzene ring. Articaine is exceptional because it contains an additional ester group that is metabolized by esterases in blood and tissue. The elimination of articaine is exponential with a half-life of 20 minutes. Since articaine is hydrolized very quickly in the blood, the risk of systemic intoxication seems to be lower than with other anesthetics, especially if repeated injection is performed.
FAQ
Contact Person: Michelle fiona
Tel: +8615512123605
